Noninfectious uveitis: strategies to optimize treatment compliance and adherence

被引：11

作者：

Dolz-Marco, Rosa ^{[1
]}

Gallego-Pinazo, Roberto ^{[1
]}

Diaz-Llopis, Manuel ^{[2
]}

Cunningham, Emmett T., Jr. ^{[3
,4
,5
,6
]}

Arevalo, J. Fernando ^{[7
,8
]}

机构：

[1] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Unit Macula, Valencia, Spain

[2] Univ Valencia, Fac Med, E-46003 Valencia, Spain

[3] Calif Pacific Med Ctr, Dept Ophthalmol, San Francisco, CA USA

[4] Stanford Univ, Dept Ophthalmol, Sch Med, Stanford, CA 94305 USA

[5] Univ Calif San Francisco, Francis I Proctor Fdn, Med Ctr, San Francisco, CA 94143 USA

[6] West Coast Retina Med Grp, San Francisco, CA USA

[7] King Khalid Eye Specialist Hosp, Vitreoretina Div, Riyadh, Saudi Arabia

[8] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21287 USA

来源：

CLINICAL OPHTHALMOLOGY | 2015年 / 9卷

关键词：

noninfectious uveitis; intraocular inflammation; immunosuppressive treatment; adherence; compliance; therapeutic failure;

D O I：

10.2147/OPTH.S36650

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Noninfectious uveitis includes a heterogenous group of sight-threatening ocular and systemic disorders. Significant progress has been made in the treatment of noninfectious uveitis in recent years, particularly with regard to the effective use of corticosteroids and non-corticosteroid immunosuppressive drugs, including biologic agents. All of these therapeutic approaches are limited, however, by any given patient's ability to comply with and adhere to their prescribed treatment. In fact, compliance and adherence are among the most important patient-related determinants of treatment success. We discuss strategies to optimize compliance and adherence.

引用

页码：1477 / 1481

页数：5

共 50 条

[1] Treatment strategies for childhood noninfectious chronic uveitis: an update
Cantarini, Luca
Simonini, Gabriele
Frediani, Bruno
Pagnini, Ilaria
Galeazzi, Mauro
Cimaz, Rolando
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (01) : 1 - 6
[2] Treatment of noninfectious uveitis
Ferreira, Lisia Barros
Farrall, Alexandra L.
Furtado, Joao M.
Smith, Justine R.
[J]. ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2021, 84 (06) : 610 - 621
[3] Sirolimus for the treatment of noninfectious uveitis
Pleyer, Uwe
Thurau, Stephan R.
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (01) : 127 - 135
[4] Biologics for the treatment of noninfectious uveitis
Lin, Chang-Ping
[J]. TAIWAN JOURNAL OF OPHTHALMOLOGY, 2018, 8 (03) : 115 - 116
[5] COMPLIANCE STRATEGIES TO OPTIMIZE ANTIDEPRESSANT TREATMENT OUTCOMES
KUPFER, DJ
[J]. JOURNAL OF CLINICAL PSYCHIATRY, 1995, 56 : 3 - 3
[6] Voclosporin as a Treatment for Noninfectious Uveitis
Schultz, Clyde
[J]. OPHTHALMOLOGY AND EYE DISEASES, 2013, 5 : 5 - 10
[7] Secukinumab in the Treatment of Noninfectious Uveitis
Hong, Jiaxu
Liu, Zuguo
Sun, Xinghuai
Xu, Jianjiang
[J]. OPHTHALMOLOGY, 2013, 120 (12) : E86 - E86
[8] Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis
Coureta, C.
Ducloyer, J-B
Touhanni, S.
Angioi-Duprez, K.
Rougier, M-B
Labalettee, P.
Titah, C.
Cochereau, I
Kodjikian, L.
Mura, F.
Chiquet, C.
Weber, M.
Bodaghi, B.
[J]. JOURNAL FRANCAIS D OPHTALMOLOGIE, 2020, 43 (04): : 341 - 361
[9] Emerging drugs for the treatment of noninfectious uveitis
Pleyer, Uwe
Pohlmann, Dominika
Kardes, Esra
Poddubnyy, Denis
Rademacher, Judith
[J]. EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (03) : 173 - 190
[10] Novel therapies in the treatment of noninfectious uveitis
Sandhu, Harpal Singh
Kaplan, Henry J.
[J]. EXPERT REVIEW OF OPHTHALMOLOGY, 2018, 13 (03) : 139 - 147

← 1 2 3 4 5 →